Daily Archives: February 8, 2021

Healthy lifestyle: Physical activities abound on college campuses like William & Mary. These healthy habits are among the benefits of college education that contribute to health and longevity, according to a study led by W&M Assistant Professor of Economics Peter Savelyev. Photo by Jim Agnew

by Nathan Warters | February 4, 2021

A study led by William & Mary Assistant Professor of Economics Peter Savelyev and funded by the National Science Foundation argues that college education leads to healthier and longer lives.

The study, Understanding the Mechanisms Linking College Education with Longevity, was published in September in Journal of Human Capital.

Researchers around the world still debate whether education affects health. Savelyev and his team support the claim that education improves heath by demonstrating the mechanisms behind this effect while using state-of-the art statistical analysis.

In our paper, we show that education increases health and longevity though healthier lifestyles, superior earnings and better work conditions, he said.

Savelyev and his co-authors examined data obtained from men and women who graduated from high school in Wisconsin in 1957. This specific timeframe was important to allow for data collection on at least a partially deceased U.S. cohort.

William & Mary News recently spoke to Savelyev about this study. The interview has been edited for length and clarity.

Variables related to healthy lifestyles that proved to be important are participating in physical exercise, maintaining a healthy body weight and abstaining from smoking tobacco. We also study the role of extremely dangerous work conditions, such as cutting trees or being exposed to infectious diseases. Educated people are less likely to face such jobs. The work conditions mechanism does not necessarily imply diminishing job-related risks for the general population, but it is a personal benefit for those who study hard and receive advanced degrees.

It is well known that many essential life determinants emerge early in life. Later in life, things are harder to change. College education is a powerful contributor to human development that increases health and longevity, among many other good effects, and it should be supported in situations when free market solutions do not work well enough.

Our simulations demonstrate that major health differences created by college education are hard to close later in life, even by strong hypothetical policy interventions, such as greatly increasing taxation of cigarettes.

Partly, this is because the effect of education is strong, and it works through many different mechanisms. It is not easy for an intervention that targets just one specific mechanism to overcome a strong effect created through dozens of mechanisms. Also, some policies, such as taxation of cigarettes, affect behavior of both the college-educated and those who did not go to college, so the effect on the difference between these two groups is small.

We find that obtaining a bachelors degree leads to about three additional years of life for men. However, we could not find any effect of college education for women, who live longer than men regardless of their education status. We identified from our data two mechanisms that partly explain the gender difference. One is that men tend to take more dangerous jobs than women. Another is that educated women of this historic cohort born in late 1930s in Wisconsin were less likely to be married, which created a negative contribution to their longevity that masked a positive contribution related to higher income. Marriage is good for your longevity. Since a negative effect of college education on marriage no longer takes place for more recent cohorts of women, we can expect a stronger effect of college on their longevity, as confirmed by our simulations.

See the original post here:
Study examines why college education leads to healthier and longer lives - William & Mary News

MOUNTAIN VIEW, Calif., Feb. 3, 2021 /PRNewswire/ --Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging.

The company licensed its AN technology from Stanford University, where it was developed by a researcher who serves as an advisor to Turn. AN technology is used to create a microenvironment that maintains stem cells in a quiescent state to repair or replace specific types of damaged tissue. The stem cell niche provides structural and trophic support and the appropriate homeostasis to regulate stem cell function.

Turn will use the niche technology in combination with its mRNA-based epigenetic reprogramming of age (ERA) technology to restore specific cells' youthful functionality, to trigger the body's ability to fight age-related diseases.

"Our artificial niche technology expands the applicability of our ERA technology to a variety of diseases involving tissue that requires a microenvironment to maintain cell quiescence," said Anja Krammer, Turn CEO. "By enveloping our ERA technology in the protective matrix of an artificial niche, we can reactivate muscle stem cells, as well as stem cells in tissues where quiescence is necessary to maintain stem cell functions."

The combined use of Turn's AN and ERA technologies may be able to restore function in hematopoietic, liver, brain, certain mesenchymal stem cells across different tissues and within the hair follicle.

This is Turn's second licensing announcement since the start of the year. Earlier, the company revealed that it acquired the global rights for its ERA technology from Stanford University, where it was developed by three researchers who founded Turn. It is the first technology to maintain cellular identity while restoring specific cells' youthful functionality, to trigger the body's ability to fight age-related diseases.

As with ERA, the company announced that it has filed for patents to protect its AN technology in major-market nations on six continents.

"This is significant for our pipeline because the combination of AN with our ERA technology in murine models shows increased potency," said Jay Sarkar, Turn's chief technology officer and a company founder who helped to develop the ERA technology. "The studies show that aged muscle stem cells treated with this combination therapy fully regenerate age-related muscle dysfunctions."

Turn's technology uses messenger RNA to produce instructions that induce cells to treat or prevent disease. Use of mRNA, which led to the quick development of two COVID-19 vaccines, promises to revolutionize the development of therapeutics by making that development safer, faster, more efficient and extremely tunable to patient need.

Turn is currently completing pre-clinical research on tailored therapies targeting indications in dermatology, ophthalmology, osteo-arthritis and cartilage damage and musculature.

ABOUT TURN BIOTECHNOLOGIES

Turn is a pre-clinical-stage company focused on repairing tissue at the cellular level. Our proprietary mRNA technology combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. Our technology provides a platform from which to attack a variety of diseases related to age. The company has the financial backing of Methuselah Fund, which focuses its investments to extend the healthy human lifespan; Formic Ventures, which invests in biotech start-ups focused on human longevity; and Shanda Group, a private global investment firm. For more information, see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT:Jim Martinez, rightstorygroup[emailprotected] or (312) 543-9026

SOURCE Turn Biotechnologies

See the rest here:
Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology - PRNewswire

Combining the directorial skills of Simon Stone, the screenplay adaptation by Moira Buffini and the cinematography of Mike Eley, The Dig portrays a dynamic, true story intertwining themes of history and modern existential longing with dramatic scenes concerning life, death, love and family.

The Netflix film, released Jan. 29, is an adaptation of John Prestons 2007 novel of the same name and is based on a true story. Taking place in the rustic countryside of Suffolk, England on the eve of World War II, self-taught archaeologist Basil Brown, played by Ralph Fiennes, embarks on a dig to uncover whats believed to be ancient Anglo-Saxon ruins potentially dating as far back as the Vikings or further.

The site lies on the vast estate owned by Edith Pretty, played by 2013s The Great Gatsby star Carey Mulligan. Pretty is a widow left with one son and a dream to dig up three large, grassy, hill-like mounds located in the fields. Though the archaeologist is unconvinced theres anything significant to be found, attempted grave robberies have convinced Pretty theres something extremely valuable hidden within.

Brown, a local archaeologist with the Ipswich Museum, leads the Sutton Hoo excavation, with Peggy Piggott, played by Lily James. Hes portrayed as a modest working man with vast knowledge of the land. His soil expertise is what leads Pretty to hire him in the first place.

Given the politics of the time period, the dig site is seen as an area of national interest as Britain was preparing to protect the countrys ancient ruins from German air raids.

The story shifts toward a more intimate focus, concerned with family and belonging, when Prettys young son Robert, played by Archie Barnes, grows increasingly fond of Brown. The two are portrayed almost as father and son, bringing the narrative closer to one of community rather than national glory.

The Dig captures a unique perspective of existentialism, with the story taking place during Britains mobilization before wartime. It keeps audiences reflecting on the significance of human legacy, wondering what will be left of us after we are gone.

As the characters on screen are forced to come to terms with their own mortality in an age of destruction and uncertainty, we get a better understanding of the significance of these ancient runes that are still standing a testament of humanitys longevity.

Aside from matters of historical and ancestral significance, The Dig is a nod to the struggles that affect ordinary people of today, with overtones of love, lust and heartbreak.

What keeps viewers satisfied throughout the film is the unchanging and breathtaking scenery of the Suffolk countryside. Eley yields cinematographic mastery by capturing the lush wheat fields of eastern England, combined with enticing pan shots of the site to emphasize how massive this project is, yet also how seemingly small of a role it plays in the full history of the nation.

Stone keeps audiences holding their breaths by turning a story of national history into a heartfelt drama that so accurately touches on struggles that afflict people of all backgrounds.

Its worth mentioning the film has received some criticism for sexist portrayal of characters, for ageism despite the whimsical setting and for fictionalizing some of the truth.

Be that as it may, it was worth the watch.

At surface level, The Dig seems like a story of historical drama, but it takes audiences into deep-cutting, emotionally luring instances of love, loss, triumph and human connection.

Read the original:
REVIEW: 'The Dig' is captivating, beautiful exploration of past The Daily Free Press - Daily Free Press

So how do you build a brand in the quick serve restaurant industry? Sure, you need a good product, and it has to be delivered efficiently.

But its that word of mouth, organic growth that may what cements your place in the industry, one that took a punch to the gut in 2020 from the coronavirus pandemic.

Thats been a key for BJ Crist and Gus Rezende with Social Entertainment, owners of the local Tropical Smoothie Caf franchises. Last month marked 11 years since Crist and Claire Foret opened the first location in Lafayette in the Oil Center, and he and Rezende have since opened four more across Acadiana.

Now they are starting another round of expansion with five more planned for south Louisiana. They will open a location on Johnston Street near E Broussard Road possibly in the fall and are looking to open in the Broussard/Youngsville area, the Scott area, the Lake Charles area and the Houma/Thibodaux area, Crist said.

Weve spent the time and effort to build the brand over 11 years, Crist said. Word of mouth is key to anything. Its what really drives longevity. Its not entirely the thing that will be the quick success story, but word of mouth is what builds a brand. Thats what weve been trying to do in trying to saturate the Acadiana area.

The expansion comes as Tropical Smoothie has emerged as one of the hotter brands in the country. Entrepreneur Magazine ranked Tropical Smoothie Caf 18th in its top 500 franchises for 2021, and last month the company reported its ninth straight year of same-store sales growth despite the turmoil many restaurants experienced when the pandemic severely limited what restaurants could do.

Tropical Smoothie Caf opened 99 new locations last year, including its 900th that opened in Georgia. It also has 254 new franchise agreements, 70% of which came from existing franchisees, and expects to open 1,000 new locations this year.

CEO Charles Watson credited the franchisees and crews for the growth despite the odds.

I'm incredibly proud of how this brand thrived during difficult circumstances and times, Watson said. Our focus on serving our guests drove us to develop new and exciting menu items and create multiple delivery methods for guests to experience all we have to offer all while heightening our dedication to safety and our commitment to the communities we serve.

The company has developed a model thats become popular by offering fruit smoothies and lighter, healthier menu items with an emphasis on customer experience, but it was the response to the pandemic that may have been the difference.

It shifted quickly at the start of the pandemic, adjusting quickly to offer curbside and delivery options and relaunching its mobile app, according to a report in QSR Magazine. It also offered franchisees 50% royalty relief for eight weeks and helped them secure PPP funding and negotiate rent relief.

The growth continued last year despite the obstacles, said Crist, who was named Multi-Unit Franchisee of the Year in August.

Its grown quite substantially in the last decade, he said. I feel like were really kind of catching our wind and the recognition. A little over a year ago they opened up on in Baton Rouge. It took a little while, but within six months it was doing some great numbers. When youre going into a new market that has no brand awareness, it usually takes a little time.

A big key, he noted, has been the customer experience. Much like Chick-Fil-A and emphasis on customer service, employees have high expectations for how they treat the customer.

Each location employs up to 25 people, many of which have gone through a screening process, Crist said. They look for employees with personality, who can hold a conversation with the customer and possibly change their day a little bit with just a little human interaction.

In turn, the company offers frequent pay raises to build continuity.

We really have high expectations on how we treat people from a hospitality standpoint, Crist said. We try to instill hospitality in the kids who work for us. I think what truly drives the success is the experience, the human factor and making people feel like, Thats my spot. Thats where I go.

Continue reading here:
Tropical Smoothie Cafe to open five more locations, including three in Acadiana - The Advocate

Thanos Tzempelikos, professor in the Lyles School of Civil Engineering, has received the prestigious Leon Gaster Award from the Society of Light and Lighting as a co-author of the paper "Cross-validation and Robustness of Daylight Glare Metrics." This award is presented annually, naming the best paper of the year concerned with lighting applications. The award was presented at the societys Annual Awards evening in December in London.

Dr. David Waters is the recipient of the Center on Aging and the Life Course's (CALC) Outstanding Professor Award.Waters is professor emeritus in the College of Veterinary Medicine and a CALC faculty associate. Waters teaches biology of aging and received numerous student nominations for the award, which recognizesexceptional teaching and mentoring of emerging scholars in aging. He is director of the Center for Exceptional Longevity Studies at the Gerald P. Murphy Cancer Foundation.

* * * * *

Orr Fellowship, a postgraduate professional development program based in Indianapolis, has recently selected four Purdue seniors as Orr fellows. The Orr Fellowship is one of Indianas most celebrated nonprofit talent programs. The students Miguel Diaz, Sean ODell, Eleanor Hamilton and Hannah Vanderbosch were chosen out of nearly 1,300 applicants and will begin at one of 46 Orr Fellowship partner companies upon graduating in May. They also will participate in Orr Fellowship programming dedicated to nurturing entrepreneurship and developing strong leadership skills.

Christine McCall, a graduate research and teaching assistant in the College of Health and Human Sciences, earned a top honor from the National Council on Family Relations for a paper. McCall won the Outstanding Student and New Professional Paper Award for her paper titled A Part of Our Family? Effects of Psychiatric Service Dogs on Quality of Life and Relationship Functioning in Military-Connected Couples.

See more here:
Appointments, honors and activities - Purdue News Service

DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ --Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health. The new capital will be used to help the companycontinue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.

"We are thrilled to announce our newest investors as we continue our quest to address this health crisis in newborns," said Timothy Brown, CEO of Evolve BioSystems. "Our research found that more than 90 percent of infants in the U.S. are missing the critical bacteria, Bifidobacterium longum subsp. infantis (B. infantis), which is widely documented as a key component of the infant gut microbiome. The financial support announced today, which includes strong continued support from our earlier investors, will help continue our mission to make a healthier future for our children during infancy and beyond."

Evolve BioSystems manufactures Evivo, a proprietary groundbreaking probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis EVC001, which studies have shown guides critical development of infants' digestive and immune systems. Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80 percent as well as significantly reducing intestinal inflammation. These pathogens are linked to higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and Type 1 Diabetes.

"Evivo, Evolve BioSystem's innovative infant probiotic, has been proven to have a dramatic impact on the developing infant gut, and to guide long-term health trajectory. This round of financing will continue to raise consumer and health care practitioner awareness, while supporting continued research and development. We are proud to partner with innovators like Tim and the entire Evolve team who are at the forefront of food and biotechnology" said Gabrielle "Ellie" Rubenstein, Co-Founder and CEO of Manna Tree. "This important investment is at the very core of our mission at Manna Tree - investing in human health."

The health benefits of Evivo are documented through numerous clinical studies and peer-reviewed publications. The investments of Manna Tree and Cargill come on the heels of the most recent breakthrough in the Evolve research, the U.S. Microbiome Survey, recently published in Scientific Reports. The research shows that nine out of ten U.S. infants are suffering from Newborn Gut Deficiency, increasing risk to early infant health and development. The study is the largest to date to benchmark the widespread levels of potential pathogenic bacteria in U.S. infants and the substantial deficiency B. infantis.

"Evolve BioSystem's Evivo has the potential to be a highly distinctive probiotic for infants and we are delighted to work with them to scale its impact," said Chuck Warta, president of Cargill's health technologies business. "Our goal is to help humans live more healthy days right from the start. Together, we can harness our respective expertise and knowledge in nutrition, digestive and immune health to bring next generation ingredient solutions to our customers."

Through its collaboration with the Bill & Melinda Gates Foundation, Evolve BioSystems is currently involved in a clinical trial at the International Centre for Diarrheal Disease Research in Bangladesh to assess the impact of Evivo on infants who have been diagnosed with severe acute malnutrition.

As part of the investment, Cargill and Manna Tree will serve as lead investors and join the company's board of directors. Other Evolve BioSystems investors in this round include Horizons Ventures, Johnson & Johnson Innovation JJDC, Inc., Spruce Capital Partners, Acre Venture Partners and Bow Capital. Evolve was spun-off from the Foods for Health Institute (FFHI) at the University of California, Davis in 2014.

For more information on Evolve BioSystems and Evivo, visit http://www.evolvebiosystems.com or http://www.evivo.com. To learn more about the Evolve BioSystems investors, visit Manna Tree at http://www.mannatreepartners.comandwww.Cargill.com.

About Evolve BioSystems, Inc

Evolve BioSystems, Inc. is a privately held microbiome company dedicated to researching solutions to establish, restore, and maintain a healthy gut microbiome. Evolve is a portfolio company of Cargill, Manna Tree, the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation. Evolve is a spin-off from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components.

About Cargill

Cargill's 155,000 employees across 70 countries work relentlessly to achieve our purpose of nourishing the world in a safe, responsible and sustainable way. Every day, we connect farmers with markets, customers with ingredients, and people and animals with the food they need to thrive.

We combine 155 years of experience with new technologies and insights to serve as a trusted partner for food, agriculture, financial and industrial customers in more than 125 countries. Side-by-side, we are building a stronger, sustainable future for agriculture. For more information, visitCargill.comand ourNews Center.

About Manna Tree

Manna Tree is a Vail, Colorado-based investment firm committed to improving human health through nutrition. The firm invests in and actively partners with growth-stage companies. We believe the future of health, well-being and longevity is attainable through innovation in food. Manna Tree has $235 million in assets under management, as of September 2020, and has made five investments to date: Vital Farms, Verde Farms, MycoTechnology, Nutriati, and Gotham Greens. http://www.mannatreepartners.com.

SOURCE Evolve BioSystems

Read the rest here:
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant...

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a marketing and distribution agreement with Atrys Health (BME: ATRY), a biomedical company dedicated to providing diagnostic services and medical treatments of excellence. Atrys Health will offer COVID-SeroKlir and COVID-SeroIndex, Kantaro's quantitative SARS-CoV-2 IgG antibody test kits, in select European and South American territories, including Spain, Portugal, Colombia, Brazil, Peru and Chile.

Atrys Health is a distributor for Kantaro quantitative antibody tests in select European and South American territories.

The Kantaro tests have received a CE Mark for detectingthe presence and precise level of neutralizingIgG antibodiesthat areproduced as part of the immune response to COVID-19 virus exposure. The Kantaro testsare also the first and only quantitative antibody tests that do not require proprietary equipment, meaning they can be run easily in anyapproved clinical laboratory.Quantitative testing for neutralizing antibodiescaninform healthcare decision-makingandpublic health policiesworldwide.

"Atrys Health is the latest in a growing list of high-qualitydistributionpartners. This agreement represents another critical step forward in bringing the Kantaro quantitative antibody tests to doctors, patients and researchers in regions affected by COVID-19," said Sara Barrington, Kantaro's chief commercial officer. "We believe this type of antibody testing is increasingly relevant at this point in the pandemic to provide peace of mindand answer important questions about vaccine response, longevityand immunity."

Isabel Lozano, CEOof Atrys Health, said: "Our partnership with Kantaro diversifies and widens our portfolio of diagnostics at the forefront of innovation. We humbly embrace the opportunity to make the Kantaro quantitative antibody testsavailableto our customers in Europe and South America and bepart of the globaleffort to increase testing and begin to recover from the COVID-19 pandemic."

COVID-SeroKlirand COVID-SeroIndexareenzyme-linked immunosorbent assays(ELISA)that havedemonstrated 97.8% sensitivityand 99.6% specificityfor detecting COVID-19 IgG antibodies, making them highly accurate with low potential for false results.The high precision results froma two-step process that utilizes two virus antigens: the receptor-binding domain(RBD)and the full-length spike protein.

Theunderlying technology in theKantaro quantitative antibody test is based on research performed attheIcahn School of Medicine at Mount Sinai in New York City.The Mount Sinai technologyhasalreadybeen used in a highly diverse population of over 86,000 patient samples to screen for convalescent plasma donors anddetermine past infections in the clinical assessment of potentially life-threatening complications from COVID-19, including lung, kidney and cardiovascular disease. This technology has been utilized extensivelyin peer-reviewed research published in ScienceandNature.

About Kantaro Biosciences

Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI plc, is dedicated to ensuring that high-quality diagnostic tests for critical health challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. For more information, visitwww.kantarobio.comand follow Kantaro on Twitter @kantarobio.

About Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.orgor find Mount Sinai on Facebook, Twitterand YouTube.

About Renalytix AI plc

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

1 Intended uses of COVID-SeroKlir may vary by country.

View original content to download multimedia:http://www.prnewswire.com/news-releases/kantaro-and-atrys-health-partnership-expand-global-footprint-of-quantitative-covid-19-antibody-tests-in-europe-and-south-america-301223660.html

SOURCE Kantaro Biosciences LLC

Read more:
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America - BioSpace